Mettrum Health Corp. (TSXV:MT.V), a fully-integrated licensed producer of premium cannabis products, launched its much-anticipated line of Mettrum Cannabis Oils.
As quoted in the press release:

Mettrum Cannabis Oils will be priced at $90 for one 40 ml bottle, which contains the equivalent medicinal content of five grams of dried marijuana. Mettrum produces whole-flower cannabis extracts using state-of-the art supercritical fluid CO2 extraction technology. The process extracts the major cannabinoids (THC and CBD), as well as the minor cannabinoids, terpenes and flavonoids that contribute to the overall medicinal value of medical cannabis. The result of this process is a highly concentrated resin. This extract is then suspended in an oil to make it easier to administer orally.  Mettrum uses medium chain triglyceride oil (MCT) in our formulations.  MCT is naturally occurring and used widely in the food, pharmaceutical and natural products industry. It is highly stable, flavourless, odourless, and allows for increased absorption making it ideal to use in cannabis oils.
Today, Mettrum is launching three oils in the Red, Blue, and Yellow categories, in line with the Mettrum Spectrum™, a trademarked system that helps physicians and their patients select the cannabis strain or strains that are most appropriate for their particular medical need. The Mettrum Spectrum™ allows for the categorization of medical cannabis products based on different ratios of key medicinal cannabinoids: cannabidiol (CBD) and tetrahydrocannabinol (THC). The Blue and Yellow category oils are notably unique as they are derived from rare strains of cannabis with a high ratio of CBD to THC  ̶  making them a relevant treatment for an expanded population of prospective patients. In the coming weeks, additional products will be added to broaden the selection across the categories that make up the Mettrum Spectrum™.
The launch comes on the heels of the announcement that Mettrum received a license from Health Canada for the production of cannabis at its new 60,000-square-foot production facility in Bowmanville, Ontario.


Mettrum Health CEO, Michael Haines, stated:

As Canada’s second LP to receive a license to sell cannabis extracts, we’ve been working hard to deliver accessibly priced, premium oils for our clients. We are responding to the demand from patients and health care professionals alike for alternative consumption methods of medical cannabis.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less